Saccharomyces boulardii and Improved Patient Global Impression of Change

Doses used in studies

mg/day: 600 (median 600, IQR 600–600) — 1 study

Time to effect

Median: 8 days · IQR 8 days–8 days · Range 8 days–8 days — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Treatment with Sb on acute inflammatory diarrhoea of viral aetiology shows no changes regarding the severity of the symptoms; nevertheless, it seems to impact improvement positively.
from: Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral

1 of 1 paper

Effectiveness of Saccharomyces Boulardii CNCM I-745 probiotic in acute inflammatory viral diarrhoea in adults: results from a single-centre randomized trial.

2023-07-03
RCT · n = 46
BMC gastroenterology 23(1)
- Marcela Ag Salazar-Parra
- Roberto U Cruz-Neri
- Xóchitl Ar Trujillo-Trujillo
- Juan J Dominguez-Mora
- Héctor I Cruz-Neri
- Jazmín M Guzmán-Díaz
- Mario J Guzmán-Ruvalcaba
- Jesús O Vega-Gastelum
- Kriscia V Ascencio-Díaz
- Maria F Zarate-Casas
- Fanny Y González-Ponce
- Francisco J Barbosa-Camacho
- Clotilde Fuentes-Orozco
- Gabino Cervantes-Guevara
- Enrique Cervantes-Pérez
- Guillermo Alonso Cervantes-Cardona
- Ana Olivia Cortés-Flores
- Alejandro González-Ojeda

PubMed: 37400812
DOI: 10.1186/s12876-023-02863-8

2 Insights on

Improved Patient Global Impression of Change

High evidence
Clinical

On day 4, 70% of patients in the Sb group and 26% in the placebo group reported improvement (P = 0.03), based on the Patients' Global Impression of Change scale

Effect: Beneficial
Effect size: Large
Significant: Yes
Dose: 600 mg/day